CJC-1295 (Without DAC)

CJC-1295 (Without DAC), also known in research literature as Modified GRF (1-29), is a synthetic peptide derived from the growth hormone-releasing hormone (GHRH) sequence. Unlike the DAC (Drug Affinity Complex) version, this form is characterized by a shorter activity duration in experimental models, allowing researchers to study pulsatile growth hormone release mechanisms in controlled laboratory conditions. This product is designed exclusively for academic, pharmaceutical, and industrial research applications.

In laboratory studies, CJC-1295 (Without DAC) is investigated for its interaction with GHRH receptors located in the pituitary gland. By stimulating these receptors, researchers examine downstream signaling pathways related to growth hormone secretion and endocrine regulation. Experimental outcomes may vary depending on research design, model systems, and administration parameters.

Because of its structural similarity to naturally occurring GHRH fragments, this peptide is frequently used to explore physiological signaling pathways associated with metabolism, tissue growth, and endocrine system regulation.

Research Overview

Research involving CJC-1295 (Without DAC) often focuses on growth hormone regulatory pathways and endocrine signaling processes. Scientists investigate how this peptide may influence hormonal signaling cascades, metabolic responses, and cellular communication in experimental environments. Analytical methods commonly used in these studies include hormone assays, receptor-binding analysis, and molecular biology techniques.

Key Research Focus Areas

• Growth Hormone Secretion: Evaluation of CJC-1295’s interaction with GHRH receptors and its potential influence on growth hormone release in laboratory models.
• Endocrine System Regulation: Investigation of hormonal signaling pathways related to pituitary and hypothalamic function.
• Metabolic Signaling: Study of how growth hormone–related pathways may influence metabolic regulation and energy balance in experimental settings.
• Pulsatile Hormone Dynamics: Analysis of short-acting peptide activity and its potential impact on natural hormone release patterns.
• Comparative Pharmacokinetics: Assessment of absorption, distribution, metabolism, and elimination characteristics in controlled research environments.

Researchers must ensure that CJC-1295 (Without DAC) is handled according to proper laboratory safety standards, including appropriate storage conditions and adherence to Good Laboratory Practice (GLP) where applicable. Accurate documentation and compliance with institutional research policies are essential.

Safety and Compliance

This product is intended for research use only and is not approved for human or animal consumption. Users must comply with all applicable laws, regulations, and laboratory guidelines when handling this compound.

For research use only. Not for human or animal consumption.